Posted On: 01/23/2016 1:15:00 PM
Post# of 37
February 8-9, 2016 The Waldorf Astoria New York
The 18th Annual BIO CEO & Investor Conference
Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. Our lead product candidate, Resunabâ„¢ is a novel synthetic oral endocannabinoid-mimetic drug that resolves chronic inflammation, bacterial infections, and fibrotic processes. Resunab is currently in Phase 2 studies for the treatment of cystic fibrosis, diffuse cutaneous systemic sclerosis and skin-predominant dermatomyositis.
30 minutes
https://www.bio.org/events/conferences/bio-ce...sentations
The 18th Annual BIO CEO & Investor Conference
Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. Our lead product candidate, Resunabâ„¢ is a novel synthetic oral endocannabinoid-mimetic drug that resolves chronic inflammation, bacterial infections, and fibrotic processes. Resunab is currently in Phase 2 studies for the treatment of cystic fibrosis, diffuse cutaneous systemic sclerosis and skin-predominant dermatomyositis.
30 minutes
https://www.bio.org/events/conferences/bio-ce...sentations
(0)
(0)Scroll down for more posts â–¼
